OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bierman Discusses CNS Involvement in Aggressive NHL

August 3rd 2018

Philip Bierman, MD, professor, Internal Medicine, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses central nervous system (CNS) involvement in aggressive subtypes of non-Hodgkin lymphoma.

Dr. Siefker-Radtke on the Treatment of FGFR-Altered Bladder Cancer

August 3rd 2018

Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with bladder cancer who have fibroblast growth factor receptor (FGFR)-altered tumors.

Dr. Baker on Integrating Palliative Care into Pediatric Oncology

August 3rd 2018

Justin N. Baker, MD, chief, Division of Quality of Life and Palliative Care, attending physician, Quality of Life Service, St. Jude Children’s Research Hospital, discusses integrating palliative care into the treatment of pediatric oncology.

Dr. Ulahannan on the PRODIGE 35 Trial in Pancreatic Cancer

August 3rd 2018

Susanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses the phase II PRODIGE 35/PANOPTIMOX trial in pancreatic cancer.

Dr. Tewari on Immunotherapeutic Strategies in Cervical Cancer

August 3rd 2018

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses immunotherapeutic strategies in cervical cancer.

Dr. Kahl on the Potential of CAR T-Cell Therapy in MCL

August 3rd 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in mantle cell lymphoma (MCL).

Dr. Wakelee on Single-Agent Immunotherapy in NSCLC

August 2nd 2018

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses single-agent immunotherapy in patients with non–small cell lung cancer (NSCLC).

Dr. Levy on Therapy for Rapidly Progressing NSCLC

August 2nd 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses therapy options for patients with rapidly progressing non–small cell lung cancer (NSCLC).

Dr. Yu on the Future of Castration-Sensitive Prostate Cancer

August 2nd 2018

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the future of castration-sensitive prostate cancer.

Dr. Shafaee on the Value of Biosimilars

August 2nd 2018

Maryam Nemati Shafaee, MD, assistant professor, Duncan Cancer Center, Lester & Sue Smith Breast Cancer, Baylor College of Medicine, discusses the value of biosimilars in oncology.

Dr. Kambhampati on Updates in Myeloma from the 2018 ASCO Annual Meeting

August 2nd 2018

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses updates in myeloma from the 2018 ASCO Annual Meeting.

Dr. Conroy on the Findings With Adjuvant mFOLFIRINOX in Pancreatic Cancer

August 2nd 2018

Thierry Conroy, MD, medical oncologist, director, Institut de Cancerologie de Lorraine, discusses the findings with an adjuvant a modified FOLFIRINOX regimen in patients with nonmetastatic pancreatic ductal adenocarcinoma.

Dr. Jabbour Discusses Blinatumomab in ALL

August 2nd 2018

Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses blinatumomab (Blincyto) in acute lymphoblastic leukemia.

Dr. Drake Discusses the Results of the CARMENA Study in RCC

August 2nd 2018

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the results of the CARMENA study in patients with metastatic renal cell carcinoma.

Dr. Choti on the Role of Surgery in Rectal Cancer

August 2nd 2018

Michael A. Choti, MD, chief of surgery, Banner MD Anderson Cancer Center, discusses the role of surgery in the treatment of patients with rectal cancer.

Dr. Tsimberidou on the Impact Trial in Patients With Advanced Cancer

August 1st 2018

Apostolia Maria Tsimberidou, MD, PhD, tenured professor, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, discusses the IMPACT trial in patients with advanced cancer.

Dr. Murthy on Future of Tucatinib in HER2+ Breast Cancer

August 1st 2018

Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the future of tucatinib in HER2-positive breast cancer.

Dr. Vokes Discusses Patient Characteristics and Immunotherapy in NSCLC

August 1st 2018

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses patient characteristics when considering immunotherapy in stage III non-small cell lung cancer.

Dr. Ligibel on the Impact of Diet and Exercise on Breast Cancer Recurrence Risk

August 1st 2018

Jennifer Ligibel, MD, senior physician, Susan F. Smith Center for Women’s Cancer at the Dana-Farber Cancer Institute, discusses the impact of diet and exercise on the risk of breast cancer recurrence.

Dr. Ellis on Abemaciclib in HR-Positive Breast Cancer

August 1st 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the use of abemaciclib (Verzenio) in hormone receptor-positive breast cancer.